GT Biopharma 1 article

Natural killer cell engager gives GT Biopharma its main biotechnology identity. Operating as a biopharmaceutical company, the organization pairs that focus with TriKE trispecific killer engager platform and NK cell immunotherapy, which clarify the modality, target or disease biology involved. The pairing of GTB-3650 CD33 TriKE and acute myeloid leukemia immunotherapy adds a second layer of entity context for GT Biopharma.

Clinical Trials & Evidence

October 8, 2026, 1:26 PM · 4 mins read

Over one hundred firms race to develop new NK cell lymphoma drugs

Clinical trials for natural killer cell lymphoma are ramping up, with more than one hundred companies and over 140 experimental drugs now in play. Novel immunotherapies and combination treatments are reshaping the field.